DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
MLN1202 is an investigational drug.
There have been 7 clinical trials for MLN1202. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2016.
The most common disease conditions in clinical trials are Cardiovascular Diseases, Atherosclerosis, and Multiple Sclerosis. The leading clinical trial sponsors are Takeda, Millennium Pharmaceuticals, Inc., and Southwest Oncology Group.
There are three US patents protecting this investigational drug and thirty-one international patents.
Recent Clinical Trials for MLN1202
|Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma||Millennium Pharmaceuticals, Inc.||Phase 1|
|Proof of Mechanism Study of MLN1202 on Atherosclerotic Inflammation in Participants With Stable Atherosclerotic Cardiovascular Disease||Takeda||Phase 2|
|Efficacy and Safety of Weekly Subcutaneous MLN1202 in Improving Diabetic Nephropathy in Participants With Macroalbuminuria||Takeda||Phase 2|
Top disease conditions for MLN1202
Top clinical trial sponsors for MLN1202
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|MLN1202||Start Trial||Methods for glycoprotein remodeling using endoglycosidase mutants||CHO Pharma Inc. (Taipei, TW) Academia Sinica (Taipei, TW)||Start Trial|
|MLN1202||Start Trial||Pretreatment of a biological sample from an autoimmune disease subject||Genentech, Inc. (South San Francisco, CA)||Start Trial|
|MLN1202||Start Trial||Chemoenzymatic glycoengineering of antibodies and Fc fragments thereof||UNIVERSITY OF MARYLAND, BALTIMORE (Baltimore, MD)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|MLN1202||European Patent Office||3532090||2036-08-24||Start Trial|
|MLN1202||South Korea||20190039580||2036-08-24||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|